London, UK – 2 January 2023. Actimed Therapeutics Ltd, a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia, a significant unmet medical need for cancer patients, and other muscle wasting disorders announces that its Chief Executive Officer, Robin Bhattacherjee, will present at the Biotech Showcase Conference 2023 in San Francisco, US.

Robin will provide an update on the company’s latest achievements and forthcoming plans, following the successful close of its second tranche of £10m total seed financing for the continued development of the company’s portfolio. This includes preparation for its Phase 2b/3 study evaluating lead asset, S-pindolol benzoate, for the treatment of cancer cachexia.

Robin Bhattacherjee commented “We look forward to presenting the company’s strong corporate and clinical progress at this year’s Biotech Showcase as we continue to develop what we hope will become a new standard of care for patients suffering from cancer cachexia. We are very pleased to have the opportunity to share these key company milestones, including our latest clinical study for S-pindolol benzoate, with investors and other key industry leaders at such a significant event for the life science community.”